Autolus Therapeutics (NASDAQ:AUTL) Shares Gap Down – Should You Sell?

Autolus Therapeutics plc (NASDAQ:AUTL) gapped down before the market opened on Tuesday . The stock had previously closed at $2.18, but opened at $2.12. Autolus Therapeutics shares last traded at $2.14, with a volume of 615,672 shares traded.

Analysts Set New Price Targets

A number of analysts recently commented on the stock. Needham & Company LLC restated a “buy” rating and issued a $10.00 price objective on shares of Autolus Therapeutics in a research report on Thursday, December 5th. Redburn Atlantic upgraded Autolus Therapeutics from a “neutral” rating to a “buy” rating and set a $13.00 price target for the company in a report on Friday, November 15th. Finally, The Goldman Sachs Group upgraded Autolus Therapeutics from a “neutral” rating to a “buy” rating and lifted their price objective for the company from $7.00 to $7.60 in a report on Monday, November 18th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $10.40.

Autolus Therapeutics Trading Up 3.2 %

The stock’s 50 day moving average is $3.28 and its two-hundred day moving average is $3.74. The stock has a market capitalization of $598.71 million, a price-to-earnings ratio of -1.86 and a beta of 1.99.

Autolus Therapeutics (NASDAQ:AUTL) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of ($0.21) by ($0.10). During the same period in the prior year, the business earned ($0.26) earnings per share. On average, research analysts anticipate that Autolus Therapeutics plc will post -0.94 earnings per share for the current year.

Institutional Trading of Autolus Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. Wellington Management Group LLP boosted its holdings in Autolus Therapeutics by 35.4% during the third quarter. Wellington Management Group LLP now owns 24,220,226 shares of the company’s stock worth $87,919,000 after purchasing an additional 6,330,392 shares during the last quarter. FMR LLC grew its holdings in shares of Autolus Therapeutics by 44.6% in the 3rd quarter. FMR LLC now owns 17,773,873 shares of the company’s stock valued at $64,519,000 after acquiring an additional 5,478,706 shares in the last quarter. Great Point Partners LLC increased its position in shares of Autolus Therapeutics by 195.0% in the second quarter. Great Point Partners LLC now owns 3,441,667 shares of the company’s stock valued at $11,977,000 after acquiring an additional 2,275,000 shares during the last quarter. Armistice Capital LLC raised its holdings in Autolus Therapeutics by 33.8% during the second quarter. Armistice Capital LLC now owns 6,250,000 shares of the company’s stock worth $21,750,000 after acquiring an additional 1,578,000 shares in the last quarter. Finally, Bank of New York Mellon Corp boosted its position in Autolus Therapeutics by 74.5% during the second quarter. Bank of New York Mellon Corp now owns 2,531,688 shares of the company’s stock valued at $8,810,000 after purchasing an additional 1,080,897 shares during the last quarter. 72.83% of the stock is currently owned by institutional investors and hedge funds.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.